One of the things that we really are facing in the field is determining who most benefits from CDK4/6 inhibition. We face this in the metastatic setting also. What are the markers of response that really can further individualize who should be getting a CDK4/6 inhibitor? Because right now, we’re really basing this decision upon clinical characteristics like stage and other high-risk features...
One of the things that we really are facing in the field is determining who most benefits from CDK4/6 inhibition. We face this in the metastatic setting also. What are the markers of response that really can further individualize who should be getting a CDK4/6 inhibitor? Because right now, we’re really basing this decision upon clinical characteristics like stage and other high-risk features. Ultimately, there’s not a predictive marker either in the blood or in the tumor tissue, but there are translational medicine efforts that are going on that are looking at plasma. Plasma was collected longitudinally. Also work that’s being done on tumor tissue like exome sequencing, etc. So hopefully those will further yield who most benefits from this approach beyond what we’re utilizing now in clinic.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
